The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Please provide your email address to receive an email when new articles are posted on . Implantable loop recorder screening for atrial fibrillation did not significantly reduce the risk for stroke ...

MOUNTAIN VIEW, Calif., Nov. 12, 2018 /PRNewswire/ -- AliveCor, the leader in artificial intelligence and FDA-cleared personal electrocardiogram (ECG) technology, today announced new medical research ...

Using an implantable loop recorder (ILR) to screen older individuals for atrial fibrillation (AF) may be more beneficial when NT-proBNP levels are high, according to a post hoc analysis of the LOOP ...